---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-24-000010"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:50:18.951703+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q1 revenue $18.1M (+25% YoY), net loss $8.9M; loan maturity extended to Sept 2026

## Summary
- Revenue $18.1M vs $14.5M in Q1 2023, driven by RNS System and DIXI Medical sales.
- Net loss $8.9M, improved from $10.4M; operating loss $7.5M vs $8.3M.
- Cash burn $7.6M, down from $9.8M; cash & investments $58.9M; debt $58.0M.
- Term loan maturity extended one year to Sept 30, 2026; PIK interest option shortened.
- FY2024 guidance reaffirmed: revenue $73-77M, gross margin 72-74%, opex $80-84M.

## SEC filing metadata
- accession: 0001528287-24-000010
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/0001528287-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/npce-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-24-000010
- JSON: https://secwatch.observer/filing/0001528287-24-000010.json
- Plain text: https://secwatch.observer/filing/0001528287-24-000010.txt

## Key facts
- Earnings Releases
  NeuroPace Inc reported the first quarter ended March 31, 2024 results: revenue $18.1 million, net income Net loss was $8.9 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $18.1 million
  - Net income: Net loss was $8.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: by specific reference in such filing. --- EX-99.1 (EX-99.1) --- NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 Extended the maturity date of the Company's term loan by one year to September 30, 2026 Maintained full-year 2024 revenue guidance of $73
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/0001528287-24-000010-index.htm
- Material Agreements
  NeuroPace Inc amended Amendment with CRG Servicing LLC, as administrative agent and collateral agent for the lenders (effective 2024-05-02).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: CRG Servicing LLC, as administrative agent and collateral agent for the lenders
  - Effective: 2024-05-02
  source text: On May 2, 2024, NeuroPace, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Company’s existing Term Loan Agreement, dated as of September 24, 2020 (as amended from time to time, the “Loan Agreement”), with the lenders party to the Loan Agreement and CRG Servicing LLC, as administrative agent and collateral agent for the lenders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828724000010/0001528287-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.